Reviewing the Safety and Efficacy of New Therapy Options in the Management and Treatment of the Influenza Virus

Description

Health systems pharmacists and retail pharmacists are ideally positioned to identify patients at greater risk for influenza related complications and in making clinical recommendations according to patient need. They can also act as patient educator and advocate by increasing awareness about modes of transmission, flu symptoms, flu related complications and available treatments. Additionally, these essential healthcare providers can educate prescribers and patients about novel antivirals and their safety and efficacy.

Speakers: James Lewis, PharmD, FIDSA, Oregon Health and Science University; Miranda Wilhelm, PharmD, Edwardsville School of Pharmacy, Southern Illinois University

Registration coming soon!

 

Pharmacist Learning Objectives

At the conclusion of this activity, learners should be better able to:

  1. Recognize the critical nature of early diagnosis and initiation of antiviral therapy especially among patient populations at high risk for influenza related complications.
  2. Evaluate the safety and efficacy of the recommended antivirals for the management and treatment of the influenza virus.
  3. Explore the clinical interventions that health systems pharmacist and the retail pharmacist can employ when educating patients about the influenza virus as well as in recommending the available antiviral therapies for the treatment of the influenza virus including novel therapies.

 

 
 

Supporter

Presented by Pharmacy Times Continuting Education.

 
Learning Level: Level 2
Track: Satellite Symposia
Session Time Slot(s): 
Date: 
Saturday, March 21
Time: 
6:00 AM - 8:00 AM
Room: 
Gaylord National Resort - Cherry Blossom Ballroom
CEUs Pharmacist: 0.15
Activity Type:
Application-based